Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.78 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.75 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8933304 | 1.00 | ADORA2A (0.78) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL6939161 | 0.90 | ADORA2A (0.85) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL7762507 | 0.90 | ADORA2A (0.85) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL5733877 | 0.89 | ADORA2A (0.81) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL5733892 | 0.89 | ADORA2A (0.81) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL18677240 | 0.88 | ADORA2A (0.80) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL18674322 | 0.88 | ADORA2A (0.80) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL5735375 | 0.88 | ADORA2A (0.73) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL5734994 | 0.88 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL5735705 | 0.88 | ADORA2A (0.79) | ADORA2AADORA2BADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024182811-A1 | COMPOSITIONS AND METHODS FOR TREATING UTERINE LEIOMYOMAS | UNIVERSITY OF SOUTH FLORIDA (US) | 2024-09-06 | — | — | WO | claimed |
| US-20230118877-A1 | ADENOSINE A2A AGONISTS FOR THE TREATMENT OF CYTOKINE STORM SYNDROME | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2023-04-20 | — | — | US | claimed |
| US-12115182-B2 | Adenosine A2A agonists for the treatment of cytokine storm syndrome | UNIVERSITY OF MARYLAND BALTIMORE (US) | 2024-10-15 | — | — | US | disclosed |
| WO-2024182811-A1 | COMPOSITIONS AND METHODS FOR TREATING UTERINE LEIOMYOMAS | UNIVERSITY OF SOUTH FLORIDA (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20230118877-A1 | ADENOSINE A2A AGONISTS FOR THE TREATMENT OF CYTOKINE STORM SYNDROME | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2023-04-20 | — | — | US | disclosed |
| CN-101068825-B | Having a2A2-propynyl adenosine analogs with modified 5' -ribose groups for agonist activity | Univ Virginia Patent Found | 2013-05-08 | — | — | CN | disclosed |
| EP-2266994-B1 | 2-propynyl adenosine analgos with modified 5'-ribose groups having A2A agonist activity | Univ Virginia Patent Found (US) | 2013-04-03 | — | — | EP | disclosed |
| EP-1778712-B1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | Univ Virginia Patent Found (US) | 2013-01-30 | — | — | EP | disclosed |
| US-8158604-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-04-17 | — | — | US | disclosed |
| US-7989431-B2 | 4-{3-[6-Amino-9-(5-cyclopropylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-cyclohexanecarboxylic acid methyl ester; for inflammation, such as organ, tissue or cell transplantation, angioplasty (PCTA), inflammation following ischemia/reperfusion, or grafting | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-08-02 | — | — | US | disclosed |
| EP-2266994-A1 | 2-propynyl adenosine analgos with modified 5'-ribose groups having A2A agonist activity | University Of Virginia Patent Foundation (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7737127-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-06-15 | — | — | US | disclosed |
| US-7605143-B2 | 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-10-20 | — | — | US | disclosed |
| CN-101068825-A | Having a2A2-propynyl adenosine analogs with modified 5' -ribose groups for agonist activity | UNIV VIRGINIA (US) | 2007-11-07 | — | — | CN | disclosed |
| US-7214665-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-05-08 | — | — | US | disclosed |
| US-20060040888-A1 | 2-propynyl adenosine analogs with modifed 5'-ribose groups having A2A agonist activity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-02-23 | — | — | US | disclosed |
| US-20030186926-A1 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186926-A1 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA2B 4/4885ADORA3 3/4885 |
| US-20060040888-A1 | 2-propynyl adenosine analogs with modifed 5'-ribose groups having A2A agonist activity | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA2B 4/4885ADORA3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.